Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06104748
Status:
RECRUITING
Last Update Posted:
2024-06-07
First Post:
2023-10-16
Brief Title:
A Cohort of Maternal Vascular Malperfusion-related FGR CoMVMFGR
Sponsor:
Shanghai First Maternity and Infant Hospital
Organization:
Shanghai First Maternity and Infant Hospital
Study Overview
Official Title:
A Cohort of Maternal Vascular Malperfusion-related FGR CoMVMFGR
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Based on a precise diagnostic standard process through a multicenter study we will establish a cohort focusing on placenta-mediated fetal growth restriction FGR Long-term follow-up will be conducted to seek predictive indicators for short-term and long-term adverse outcomes of maternal vascular malperfusion-related FGR MVM-FGR
Detailed Description:
Fetal Growth Restriction FGR denotes the inability of fetal growth to attain its inherent genetic potential due to diverse pathological influences It stands as a significant determinant of morbidity and mortality during the perinatal phase intricately linked with adverse long-term consequences The etiology of FGR is complex involving maternal placentalumbilical and fetal factors Among these maternal vascular malperfusion-related FGR MVM-FGR emerges as the prevalent subtype which is considered to have potential for early intervention and prevention
To address this we will establish a cohort dedicated to MVM-FGR guided by a stringent diagnostic standard process tailored for FGR Our objective is to compile a comprehensive dataset of singleton pregnancies diagnosed with MVM-FGR cases through multicenter collaboration The definition of FGR aligns with the FIGO consensus criteria We conduct thorough prenatal screenings for fetal factors including genetic abnormalities infections and structural anomalies subsequently enrolling MVM-FGR cases into our cohort
Techniques including Doppler ultrasound magnetic resonance imaging MRI and electronic fetal heart monitoring will be employed to assess fetal conditions Follow-up continues until the child reaches the age of two years postpartum Pathological examination of the placenta is performed after delivery with additional placental genetic testing if necessary
To address this we will establish a cohort dedicated to MVM-FGR guided by a stringent diagnostic standard process tailored for FGR Our objective is to compile a comprehensive dataset of singleton pregnancies diagnosed with MVM-FGR cases through multicenter collaboration The definition of FGR aligns with the FIGO consensus criteria We conduct thorough prenatal screenings for fetal factors including genetic abnormalities infections and structural anomalies subsequently enrolling MVM-FGR cases into our cohort
Techniques including Doppler ultrasound magnetic resonance imaging MRI and electronic fetal heart monitoring will be employed to assess fetal conditions Follow-up continues until the child reaches the age of two years postpartum Pathological examination of the placenta is performed after delivery with additional placental genetic testing if necessary
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None